Thibaudin M, Roussot N, Burlot C, Schmitt A, Vincent J, Tharin Z, Bengrine L, Bellio H, Bertaut A, Hampe L, Daumoine S, Rederstorff E, Peroz M, Huppe T, Derangère V, Rageot D, Simard J, Truntzer C, Fumet JD, Ghiringhelli F

Signal Transduct Target Ther. 2025 01 17;10(1):22

Plasma clearance of 5-fluorouracil is more influenced by variations in glomerular filtration rate than by uracil concentration.

Matheux A, Collas L, Grisard M, Goulaieff L, Ghiringhelli F, Bengrine-Lefevre L, Vincent J, Goirand F, Royer B, Schmitt A

Cancer Chemother Pharmacol. 2024 12 19;95(1):9

Large-Scale DPD Testing Should Be More Than an Option.

Etienne-Grimaldi MC, Royer B, Launay M, Schmitt A, Thomas F, Ciccolini J,

JCO Oncol Pract. 2024 12 3;:OP2400464

Attributes for a discrete-choice experiment on preferences of patients for oncology pharmacy consultations.

Damerval M, Bennani M, Rioufol C, Omrani S, Riboulet M, Etienne-Selloum N, Saint-Ghislain A, Leenhardt F, Schmitt A, Simon N, Clairet AL, Meurisse A, ,Nerich V

Support Care Cancer. 2024 04 30;32(5):318

Improving olaparib exposure to optimize adverse effects management.

Sterlé M, Puszkiel A, Burlot C, Pereira E, Bellesoeur A, De Percin S, Beinse G, Fumet JD, Favier L, Niogret J, Blanchet B, Royer B, Bengrine-Lefevre L, Schmitt A

Ther Adv Med Oncol. 2024 04 24;16:17588359241248328

The harms of inappropriate digoxin prescribing in cancer patients : a drug-drug interaction with posaconazole.

Sterlé M, Schmitt A, Boulin M

Ann Pharm Fr. 2024 04 22;:

Screening and management of metabolic complications of mTOR inhibitors in real-life settings.

Spanjaard P, Petit JM, Schmitt A, Vergès B, Bouillet B

Ann Endocrinol (Paris). 2023 12 1;:

Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.

Carras S, Torroja A, Emadali A, Montaut E, Daguindau N, Tempescul A, Moreau A, Tchernonog E, Schmitt A, Houot R, Dartigeas C, Barbieux S, Corm S, Banos A, Fouillet L, Dupuis J, Macro M, Fleury J, Jardin F, Sarkozy C, Damaj G, Feugier P, Fornecker LM, Chabrot C, Dorvaux V, Bouabdallah K, Amorim S, Garidi R, Voillat L, Joly B, Morineau N, Moles MP, Zerazhi H, Fontan J, Arkam Y, Alexis M, Delwail V, Vilque JP, Ysebaert L, Burroni B, Callanan M, Le Gouill S, Gressin R

Haematologica. 2023 11 30;:

Case report: 5-Fluorouracil treatment in patient with an important partial DPD deficiency.

Schmitt A, Royer B, Boidot R, Berthier J, Ghiringhelli F

Front Oncol. 2023 06 20;13:1187052

Pharmacokinetics and Pharmacodynamic of Alpelisib.

Royer B, Kaderbhaï CG, Schmitt A

Clin Pharmacokinet. 2023 01 12;:

Novel fat taste receptor agonists curtail progressive weight gain in obese male mice.

Khan AS, Hichami A, Murtaza B, Louillat-Habermeyer ML, Ramseyer C, Azadi M, Yesylevskyy S, Mangin F, Lirussi F, Leemput J, Merlin JF, Schmitt A, Suliman M, Bayardon J, Semnanian S, Jugé S, Khan NA

Cell Mol Gastroenterol Hepatol. 2022 11 18;:

AFSOS-SFRO-SFH-SFNEP-SFCE-GFRP guidelines on radio-induced nausea and vomiting.

Faivre JC, Tomaszewski F, Demoor-Goldschmitt C, Beddok A, Malgras A, Schmitt A, Fabre J, Perrot A, Jovenin N, Salleron J, Clavère P, Pointreau Y, Scotté F, Bensadoun RJ, Block V, Thariat J

Crit Rev Oncol Hematol. 2022 10 9;:103825

Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency.

Maillard M, Launay M, Royer B, Guitton J, Gautier-Veyret E, Broutin S, Tron C, Le Louedec F, Ciccolini J, Richard D, Alarcan H, Haufroid V, Tafzi N, Schmitt A, Etienne-Grimaldi MC, Narjoz C, Thomas F,

Br J Clin Pharmacol. 2022 09 14;:

[Practical management of PARP inhibitors: A French DELPHI consensus].

Selle F, Boffa JJ, Etienne G, Angelergues A, Augereau P, Berton D, Dielenseger P, Fabbro M, Falandry C, Follana P, Gladieff L, Joly F, Kurtz JE, Matta C, Mouret-Reynier MA, Schmitt A, Scotté F, Marjollet C, Floquet A

Bull Cancer. 2022 09 12;:

Smartphone-based application and nurses' interventions for symptoms monitoring in patients treated with oral anticancer agents: A 1-year follow-up in a tertiary cancer center.

Porcher L, Perron V, Blanc J, Kaderbhai CG, Tharin Z, Schmitt A, Gallet M

J Oncol Pharm Pract. 2022 08 8;:10781552221117731

Adherence to oral anti-cancer therapies in older patients is similar to that of younger patients.

Lory P, Perche L, Blanc J, Fouquier B, Giroux A, Thomassin A, Devaux M, Renaudin A, Di Martino C, Quipourt V, Bengrine-Lefèvre L, Schmitt A

J Oncol Pharm Pract. 2022 05 29;:10781552221103547

Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach.

Reda M, Macaire P, Bellio H, Uwer L, Ilie S, Lorgis V, Hennequin A, Ladoire S, Rederstorff E, Fumoleau P, Isambert N, Bonnin N, You B, Freyer G, Desmoulins I, Schmitt A

Cancer Chemother Pharmacol. 2022 Jan 8;:

Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients.

Marouille AL, Petit E, Kaderbhaï C, Desmoulins I, Hennequin A, Mayeur D, Fumet JD, Ladoire S, Tharin Z, Ayati S, Ilie S, Royer B, Schmitt A

Pharmaceutics. 2021 Oct 16;13(10):

Trastuzumab-emtansine induced pleural and pericardial effusions.

Lombardi J, Lory P, Martin N, Mayeur D, Combret S, Grandvuillemin A, Boulay C, Schmitt A

J Oncol Pharm Pract. 2021 May 18;:10781552211015772

Intravenous high-dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: an LOC network study.

Lam M, Touitou V, Choquet S, Cassoux N, Ghesquières H, Kodjikian L, Schmitt A, Gattoussi S, Tabouret É, Sampo M, Blonski M, Angioi-Duprez K, Houot R, Mouriaux F, Gyan E, Le Lez ML, Moles MP, Croisé F, Chauchet A, Schwartz C, Ahle G, Meyer L, Gressin R, Chiquet C, Oberic L, Ollé P, Marolleau JP, Jany B, Tempescul A, Cochener B, Damaj G, Quintyn JC, Chabrot C, Rousseau E, Franciane P, Schneider C, Massé H, Bonnefoy JT, Brézin A, Fornecker LM, Ballonzoli L, Le Garff-Tavernier M, Hoang-Xuan K, Bodaghi B, Soussain C, Houillier C

Am J Hematol. 2021 Apr 17;:

Population Pharmacokinetics of Palbociclib in aReal-World Situation.

Royer B, Kaderbhaï C, Fumet JD, Hennequin A, Desmoulins I, Ladoire S, Ayati S, Mayeur D, Ilie S, Schmitt A

Pharmaceuticals (Basel). 2021 Feb 24;14(3):

Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients.

Lunar N, Etienne-Grimaldi MC, Macaire P, Thomas F, Dalenc F, Ferrero JM, Pivot X, Milano G, Royer B, Schmitt A

Cancer Chemother Pharmacol. 2021 Jan 2;:

Lipoproteins LDL versus HDL as nanocarriers to target either cancer cells or macrophages.

Hadi T, Ramseyer C, Gautier T, Bellaye PS, Lopez T, Schmitt A, Sarah F, Yesylevskyy S, Minervini T, Douhard R, Dondaine L, Proukhnitzky L, Messaoudi S, Wendremaire M, Moreau M, Neiers F, Collin B, Denat F, Lagrost L, Garrido C, Lirussi F

JCI Insight. 2020 Nov 24;:

Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure.

Dolat M, Macaire P, Goirand F, Vincent J, Hennequin A, Palmier R, Bengrine-Lefevre L, Ghiringhelli F, Royer B, Schmitt A

Pharmaceuticals (Basel). 2020 Nov 23;13(11):

Exposure-Response Analysis of Raltitrexed Assessing Liver Toxicity.

Royer B, Schmitt A, Nguyen T, Paillard MJ, Jary M, Demarchi M, Vernerey D, Henriques J, Jacquin M, Borg C, Kim S

Br J Clin Pharmacol. 2020 Aug 12;:

Lack of everolimus diffusion in pleural fluid during pleural progression of breast cancer: A case report.

Vaury C, Macaire P, Goirand F, Coudert B, Guérard P, Schmitt A

J Oncol Pharm Pract. 2020 Jun 3;:1078155220927771

Impact of G-CSF on FOLFIRINOX-induced neutropenia prevention: a population PK/PD approach.

Macaire P, Paris J, Vincent J, Ghiringhelli F, Bengrine-Lefevre L, Schmitt A

Br J Clin Pharmacol. 2020 May 9;:

A simple and fast LC-MS/MS method for the routine measurement of cabozantinib, olaparib, palbociclib, pazopanib, sorafenib, sunitinib and its main active metabolite in human plasma.

Jolibois J, Schmitt A, Royer B

J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.. 2019 Oct 21;1132:121844

Therapeutic drug monitoring as a tool to optimize 5-FU-based chemotherapy in gastrointestinal cancer patients older than 75 years.

Macaire P, Morawska K, Vincent J, Quipourt V, Marilier S, Ghiringhelli F, Bengrine-Lefevre L, Schmitt A

Eur. J. Cancer. 2019 Mar 5;111:116-125

Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer.

Devaux M, Gerard L, Richard C, Bengrine-Lefevre L, Vincent J, Schmitt A, Ghiringhelli F

World J Clin Oncol. 2019 Feb 24;10(2):75-85

How can we best monitor 5FU administration to maximize benefit to risk ratio?

Goirand F, Lemaitre F, Launay M, Tron C, Chatelut E, Boyer JC, Bardou M, Schmitt A

Expert Opin Drug Metab Toxicol. 2018 Nov 19;:

[5-fluorouracil therapeutic drug monitoring: Update and recommendations of the STP-PT group of the SFPT and the GPCO-Unicancer].

Lemaitre F, Goirand F, Launay M, Chatelut E, Boyer JC, Evrard A, Paludetto MN, Guilhaumou R, Ciccolini J, Schmitt A

Bull Cancer. 2018 Sep;105(9):790-803

Better characterization of vinflunine pharmacokinetics variability and exposure/toxicity relationship to improve its use: Analyses from 18 trials.

Schmitt A, Nguyen L, Zorza G, Ferré P, Pétain A

Br J Clin Pharmacol. 2018 05;84(5):900-910

[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].

Loriot MA, Ciccolini J, Thomas F, Barin-Le-Guellec C, Royer B, Milano G, Picard N, Becquemont L, Verstuyft C, Narjoz C, Schmitt A, Bobin-Dubigeon C, Harle A, Paci A, Poinsignon V, Quaranta S, Evrard A, Hennart B, Broly F, Fonrose X, Lafay-Chebassier C, Wozny AS, Masskouri F, Boyer JC, Etienne-Grimaldi MC

Bull Cancer. 2018 Apr;105(4):397-407